Changes following supplementation with lutein and zeaxanthin in retinal function in eyes with early age-related macular degeneration: a randomised, double-blind, placebo-controlled trial

British Journal of Ophthalmology
Q1
Sep 2014
Citations:44
Influential Citations:4
Interventional (Human) Studies
82
S2 IconPDF Icon

Enhanced Details

Methods
Randomized, double-blind, placebo-controlled trial conducted in Beijing, China; 112 adults with early age-related macular degeneration (age >50); four parallel groups (10 mg lutein, 20 mg lutein, lutein 10 mg + zeaxanthin 10 mg, placebo) over 2 years.
Intervention
10 mg lutein daily; 20 mg lutein daily; lutein 10 mg/day + zeaxanthin 10 mg/day; or placebo daily for 2 years.
Results
MPOD increased significantly in active groups vs placebo (p<0.05). N1P1 response densities increased in ring 1 and ring 2 after 48 weeks in all active treatments; rings 3–6 showed no significant changes. Mean retinal sensitivity (MRS) increased with either 10 mg or 20 mg lutein; placebo showed no MRS improvement. At 2 years, MRS at 1° eccentricity was higher in the 10 mg lutein (13.37 dB) and 20 mg lutein (12.55 dB) groups vs placebo (10.32 dB) (p<0.05). Lutein/zeaxanthin supplementation increases MPOD; supplementary lutein enhances retinal sensitivity in early AMD; these changes may support central vision in this population.
Limitations
Highly selective eligibility; limited generalizability; no meso-zeaxanthin in the formulation and no zeaxanthin-only control; unable to determine effect on AMD progression due to sample size and study duration.

Abstract

Aims To investigate functional and macular pigment (MP) changes in patients with early age-related macular degeneration (AMD) after multiple supplementation with lutein and zeaxanthin. Methods 112 patients with early AMD were randomly (1:1:1:1) assig...